MBP-426 is a transferrin-conjugated nano
particle formulation of oxaliplatin.
Oxaliplatin is a blockbuster drug used in
combination with fluorouracil and leucovorin
(FOLFOX), which is FDA-approved treatment for
MBP-426 improves the safety and efficacy of
oxaliplatin by dual mode of action of our
nano-particles. This has been shown in the phase I
study for solid tumors under the US IND (#73,251).
Currently, Phase IIa study is ongoing in US for
the indication of gastric and gastroesophageal
MBP-Y003 is a transferrin-conjugated nano
particle formulation of methotrexate(MTX) for the
indication of Lymphoma and other cancers.
MTX is a popular antifiolic and antimetabolite
drug and broadly used for cancer treatment.
The antitumor activity of MBP-Y003 was
evaluated using human xenograft tumor models. This
study has demonstrated that MBP-Y003 has potential
antitumor activity against various tumor cell
lines such as prostate cancers and lymphomas.
MBP-Y003b is a comprehensive version of
MBP-Y003 for chronic inflammatory diseases such as
rheumatoid arthritis (RA).
Nano-sized particles preferentially extravasate
into inflamed tissue with vascular hyper
permeability. Furthermore, transferrin mediates
MTX internalization into pathology-related
activated immune cells, known to highly express
Although MTX is the standard drug for RA
treatment, 15% of patients fail to respond MTX and
many MTX-responsive patients cannot tolerate the
side effects of the drug. Recently, anti-TNF-alpha
agents were introduced and demonstrated to be
clearly beneficial for RA treatment, but
combination with MTX is still required and
importance of MTX is not diminished. The
improvement of MTX efficacy and safety achieved by
MBP-Y003 formulation has a great potential to make
great advantage on RA treatment.
MBP-Y004 is a transferrin-conjugated nano
particle formulation of Docetaxel, used for
ovarian, breast and non-small cell lung
MBP-Y005 is a transferrin-conjugated nano
particle formulation of Gemsitabine, which is a
nucleoside used for cancer treatment such as
non-small cell lung cancer, pancreatic cancer and